janneke2024-08-26T10:01:05+02:00 Case study – Target validation by combining Oncolines® profiling and gene dependency screens Case study – Target validation by combining Oncolines® profiling and gene dependency screens Case study – Target validation by combining Oncolines® profiling and gene dependency screens
Oncolines®2024-08-26T10:54:25+02:00 Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™
Oncolines®2023-05-29T15:59:34+02:00 Case study – Synergistic interaction of olaparib and cisplatin Case study – Synergistic interaction of olaparib and cisplatin Case study – Synergistic interaction of olaparib and cisplatin
Oncolines®2024-03-18T16:59:40+01:00 Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib
Oncolines®2023-05-29T15:58:13+02:00 Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer
janneke2023-05-29T15:56:23+02:00 Case study – Gene expression profiling to understand and combat drug resistance Case study – Gene expression profiling to understand and combat drug resistance Case study – Gene expression profiling to understand and combat drug resistance
Oncolines®2024-07-04T09:50:26+02:00 Case study – Combination matrix to determine Bliss independence synergy scores Case study – Combination matrix to determine Bliss independence synergy scores Case study – Combination matrix to determine Bliss independence synergy scores
Oncolines®2023-05-29T16:00:20+02:00 Case study – TTK patient stratification marker Case study – TTK patient stratification marker Case study – TTK patient stratification marker
Oncolines®2023-05-29T16:01:07+02:00 Case study – MEK inhibitor Case study – MEK inhibitor Case study – MEK inhibitor
Oncolines®2023-05-29T16:01:43+02:00 Case study – Kadcyla® Case study – Kadcyla® Case study – Kadcyla®
yvonne2024-07-03T11:49:07+02:00 Case study – 3D spheroid drug sensitivity Case study – 3D spheroid drug sensitivity Case study – 3D spheroid drug sensitivity
Oncolines®2024-08-26T10:54:25+02:00 Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™
Oncolines®2024-08-26T10:52:53+02:00 Case study – Characterization of TTK Inhibitors Case study – Characterization of TTK Inhibitors Case study – Characterization of TTK Inhibitors
Oncolines®2024-08-26T10:52:37+02:00 Case study – BTK Inhibitor ibrutinib Case study – BTK Inhibitor ibrutinib Case study – BTK Inhibitor ibrutinib
Oncolines®2024-08-26T10:51:14+02:00 Case study – BTK inhibitor fenebrutinib Case study – BTK inhibitor fenebrutinib Case study – BTK inhibitor fenebrutinib
Oncolines®2024-08-26T10:52:29+02:00 Case study – Arginase-1 Inhibitors Case study – Arginase-1 Inhibitors Case study – Arginase-1 Inhibitors
